AU2001282746A1 - Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors - Google Patents

Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors

Info

Publication number
AU2001282746A1
AU2001282746A1 AU2001282746A AU8274601A AU2001282746A1 AU 2001282746 A1 AU2001282746 A1 AU 2001282746A1 AU 2001282746 A AU2001282746 A AU 2001282746A AU 8274601 A AU8274601 A AU 8274601A AU 2001282746 A1 AU2001282746 A1 AU 2001282746A1
Authority
AU
Australia
Prior art keywords
phenylheteroazetidines
novel
useful
nitric oxide
oxide synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282746A
Inventor
David Cheshire
Timothy Luker
Antonio Mete
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001282746A1 publication Critical patent/AU2001282746A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AU2001282746A 2000-08-04 2001-07-31 Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors Abandoned AU2001282746A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0019006 2000-08-04
GB0019006A GB0019006D0 (en) 2000-08-04 2000-08-04 Novel compounds
PCT/SE2001/001688 WO2002012187A1 (en) 2000-08-04 2001-07-31 Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors

Publications (1)

Publication Number Publication Date
AU2001282746A1 true AU2001282746A1 (en) 2002-02-18

Family

ID=9896865

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282746A Abandoned AU2001282746A1 (en) 2000-08-04 2001-07-31 Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors

Country Status (3)

Country Link
AU (1) AU2001282746A1 (en)
GB (1) GB0019006D0 (en)
WO (1) WO2002012187A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200305395A (en) * 2002-03-15 2003-11-01 Novartis Ag Organic compounds
JP2005532293A (en) * 2002-04-18 2005-10-27 ファルマシア・コーポレーション Monotherapy for the treatment of Parkinson's disease using cyclooxygenase-2 (COX2) inhibitors
JP2005528403A (en) * 2002-04-18 2005-09-22 ファルマシア・コーポレーション Combination therapy for treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitors
RU2006100298A (en) 2003-06-11 2006-05-10 Мерк энд Ко., Инк. (US) SUBSTITUTED 3-ALKYL-AND 3-ALKENYLASETIDINE DERIVATIVES
EP1868434A4 (en) * 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc Beta-lactamylalkanoic acids for treating premenstrual disorders
AU2013206201B2 (en) * 2005-03-22 2016-06-16 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
DK1910346T3 (en) 2005-07-19 2019-05-27 Azevan Pharmaceuticals Inc BETA-LACTAMYL FENYLALANINE, CYSTEIN AND SERIN VASOPRESSIN ANTAGONIST
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
MX2016012645A (en) 2014-03-28 2017-01-11 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases.
BR112020005107A2 (en) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. compositions and methods for the treatment of brain injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ292135B6 (en) * 1997-02-10 2003-08-13 Pfizer Products Inc. 2-Amino-6-(2-substituted-4-phenoxy)substituted pyridines, their use and pharmaceutical preparations based thereon
FR2764889B1 (en) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AP2001002326A0 (en) * 1999-05-21 2001-12-31 Pfizer Prod Inc New pharmaceuticals combinations for nos inhibitors.

Also Published As

Publication number Publication date
WO2002012187A1 (en) 2002-02-14
GB0019006D0 (en) 2000-09-20

Similar Documents

Publication Publication Date Title
GB0031179D0 (en) Nitric oxide synthase inhibitors
HK1220636A1 (en) Immunostimulatory g,u-containing oligoribonucleotides gu-
AU4774501A (en) Amidino compounds useful as nitric oxide synthase inhibitors
AU2002222252A1 (en) Nitric oxide synthase inhibitor phosphate salt
AU2002336401A1 (en) Nitric oxide generation
AU2002317910A1 (en) Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof
AU2001258771A1 (en) -secretase inhibitors
AU2001295732A1 (en) Concatenated nucleic acid sequences
EP1282413A4 (en) Halogenated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
MXPA03000772A (en) Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase.
AU2625201A (en) Glycogen synthase kinase-3 inhibitors
MXPA03002207A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors.
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2001253519A1 (en) Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AU5248800A (en) Fading inhibitors
MXPA02012890A (en) Methods for increasing nitric oxide synthase activity.
AU2003272719A1 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
AU2001282746A1 (en) Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors
AU2002304853A1 (en) Substituted benzopyranones as telomerase inhibitors
EP1282420A4 (en) Halogenated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AU6594401A (en) 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
AU2001280591A1 (en) Modulation of nitric oxide synthase by pkc
MXPA03002271A (en) 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors.
AU2002350575A1 (en) Selective neuronal nitric oxide synthase inhibitors
AU2001286212A1 (en) Rare-earth ternary complex